FindTrial
Sign In

A phase II/III clinical study of R442 (Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.

A phase II/III clinical study of R442 (Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220384
Enrollment
Unknown
Registered
2007-04-26
Start date
2007-04-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

investigational material(s) Generic name etc : R422 (Pegylated Interferon alfa-2a) INN of investigational material : Therapeutic category code : 639 Other biological preparations Dosage and Administr

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and Female patients aged 20 years-old or more, diagnosed chronic hepatitis B.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026